دورية أكاديمية
Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
العنوان: | Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. |
---|---|
المؤلفون: | Jokar MH; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran., Baghbani B; North Khorasan University of Medical Sciences, Bojnord, Iran., Geraylow KR; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran., Shariati J; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran., Mehrad-Majd H; Department of Clinical Research Development, Ghaem Hospital, Mashhad University of Medical Sciences, Iran., Mirfeizi Z; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran., Hashemzadeh K; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran. |
المصدر: | Reumatologia [Reumatologia] 2022; Vol. 60 (6), pp. 392-398. Date of Electronic Publication: 2022 Dec 30. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Termedia Country of Publication: Poland NLM ID: 20130190R Publication Model: Print-Electronic Cited Medium: Print ISSN: 0034-6233 (Print) Linking ISSN: 00346233 NLM ISO Abbreviation: Reumatologia Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Publication: 2005- : Poznań : Termedia Original Publication: 1963-1992 : Warszawa : Panstwowy Zakład Wydawnictw Lekarskich |
مستخلص: | Introduction: Systemic sclerosis (SSc) is an autoimmune, connective tissue disorder of unknown etiology which causes vasculopathy and fibrosis. Raynaud's phenomenon (RP) is a common complication of SSc, which leads to ischemia and gangrenes. Treatment of RP is a clinical problem and often remains insufficient.This study aimed to evaluate the therapeutic efficacy of local injections of botulinum toxin type A (BTX-A) in improving the symptoms of Raynaud's phenomenon (RP) secondary to scleroderma. Material and Methods: This parallel single-blinded, placebo-controlled clinical trial enrolled 29 patients with scleroderma. Participants received BTX-A in the first, 2 nd , 3 rd , and 4 th dorsal web spaces and the base of the thumb and small finger of the non-dominant hand and 2.5 ml of sterile normal saline in the opposite hand. Pre-injection measurements and post-injection follow-up evaluations at months 1 and 4 were performed. We compared the outcomes using the paired Student's t -test. Results: The change in pain severity between pre-injection and month 1 follow-up was significantly larger in the BTX-A group ( p -value = 0.04). Between pre-injection and month 1 and month 4, the changes in the Raynaud's condition score (RCS) ( p -value = 0.02, 0.004, respectively) and the number of Raynaud's attacks ( p -value = 0.006, 0.001, respectively) were significantly greater in the BTX-A group. No significant difference was found in terms of paresthesia, skin thickening, upper extremity function, ulcer diameter, number of ulcers, or Raynaud's attack duration between the two groups ( p -value > 0.05). In time, the decrease in pain severity, paresthesia, RCS, number of ulcers, and ulcer diameter, and the increase in upper extremity function were significantly greater in the BTX-A group as compared to the placebo group ( p < 0.05). Conclusions: Our study showed that local injection of BTX-A is safe and has beneficial therapeutic effects on RP and RP-related digital ulcers in SSc patients. Competing Interests: The authors declare no conflict of interest. (Copyright: © 2022 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.) |
References: | Dermatol Ther. 2020 Nov;33(6):e14182. (PMID: 32794364) Reumatol Clin (Engl Ed). 2021 Jun-Jul;17(6):357-363. (PMID: 32591260) Ann Plast Surg. 2015 Dec;75(6):637-43. (PMID: 26418780) Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101684. (PMID: 33965340) Arch Med Sci. 2016 Aug 1;12(4):864-70. (PMID: 27478469) J Hand Surg Am. 2009 Mar;34(3):446-52. (PMID: 19258141) Arthritis Rheum. 2013 Nov;65(11):2737-47. (PMID: 24122180) J Hand Surg Am. 2010 Dec;35(12):2085-92. (PMID: 21134617) Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H2124-32. (PMID: 11668074) Ann Chir Plast Esthet. 2013 Dec;58(6):658-62. (PMID: 22204894) J Scleroderma Relat Disord. 2020 Jun 1;5(2):130-136. (PMID: 34095502) J Hand Surg Eur Vol. 2014 Oct;39(8):876-80. (PMID: 24369360) J Dermatol. 2016 Jan;43(1):56-62. (PMID: 26173902) Ann Plast Surg. 2016 Sep;77(3):318-23. (PMID: 26808752) Eur J Clin Invest. 2004 Apr;34(4):312-3. (PMID: 15086364) Plast Reconstr Surg. 2007 Jan;119(1):217-226. (PMID: 17255677) Nat Rev Rheumatol. 2010 Aug;6(8):453-60. (PMID: 20585340) J Clin Invest. 2007 Mar;117(3):557-67. (PMID: 17332883) J Bone Joint Surg Am. 2005 May;87(5):1038-46. (PMID: 15866967) J Rheumatol. 1995 Jul;22(7):1281-5. (PMID: 7562759) Plast Reconstr Surg. 2009 Jul;124(1):191-201. (PMID: 19568080) Rheum Dis Clin North Am. 2015 Aug;41(3):419-38. (PMID: 26210127) Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. (PMID: 22588748) Arthritis Rheumatol. 2017 Aug;69(8):1661-1669. (PMID: 28426903) Eur J Rheumatol. 2018 Dec;5(4):224-229. (PMID: 30501848) Rheumatol Int. 2021 May;41(5):943-949. (PMID: 32447423) Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595) |
فهرسة مساهمة: | Keywords: Raynaud’s phenomenon; botulinum toxin type A; systemic sclerosis |
تواريخ الأحداث: | Date Created: 20230123 Latest Revision: 20230124 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9847105 |
DOI: | 10.5114/reum.2022.120757 |
PMID: | 36683833 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!